NCT02922166

Effects of SRX246 on an Experimental Model of Fear and Anxiety in Humans

Effects of SRX246, a Vasopressin Receptor (V1a) Antagonist, on an Experimental Model of Fear and Anxiety in Humans

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 36 (actual)
• Sponsor: Azevan Pharmaceuticals · Industry
• Sex: All
• Age: 21 Years – 50 Years
• Healthy volunteers: Accepted

Summary

To determine the effects of SRX246 on fear and anxiety based on fear-potentiated startle in humans. Additionally, the effects of the compound on emotion recognition will be explored.

Detailed description

The study will use a double-blind, cross-over design in which each subject will receive placebo and SRX246 for 5-7 days before testing (given in counter-balanced order). The study will examine the effect of the drug on the potentiation of startle using a well-established paradigm that involves anticipation of no-shock, predictable shock, and unpredictable shock. Drug effects on emotion recognition will also be explored.

Conditions

• Fear
• Anxiety

Interventions

Type	Name	Description
DRUG	SRX246	oral capsule
DRUG	Placebo	oral capsule

Timeline

• Start date: 2017-02-03
• Primary completion: 2019-05-10
• Completion: 2019-12-01
• First posted: 2016-10-04
• Last updated: 2019-06-10

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study